文献速递乳腺癌放疗

35岁以下女性乳腺癌10年结局:局部失败风险更高,保乳治疗仍适用

10-Year Breast Cancer Outcomes in Women ≤35 Years of Age.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-10-24

该研究基于单中心1990–2010年529例≤35岁浸润性乳腺癌患者,中位随访10.3年,比较36–50岁和51–70岁对照组。超年轻患者局部失败风险显著高于36–50岁组(HR 2.2)和51–70岁组(HR 3.1),生存与复发结局更差;保乳治疗适用,放疗未显著增加第二恶性肿瘤或对侧乳腺癌。

要点

  • ≤35岁乳腺癌患者局部失败风险显著高于36–50岁和51–70岁对照组。
  • 肿瘤大小、脉管侵犯、ER阳性、辅助化疗和黑人种族与总生存独立相关。
  • 放疗未显著增加第二恶性肿瘤或对侧乳腺癌风险。

核心结论

  • ≤35岁乳腺癌患者生存与复发结局劣于36–50岁或51–70岁患者。
  • 基于该数据,保乳治疗对≤35岁患者是合适的。
  • 对第二恶性肿瘤的担忧不应影响术后放疗的已知适应证。

研究设计与样本

  • 对照组为36–50岁(n=6246)和51–70岁(n=7294)患者,来自机构登记数据库。
  • 采用卡方检验比较分类变量频率,Kaplan-Meier法评估生存终点,多变量分析评估总生存相关因素。

主要发现

  • ≤35岁患者中位诊断年龄32岁(范围20–35),中位随访10.3年。
  • 多变量分析中与总生存相关的因素:肿瘤大小(HR 1.14,P=.02)、脉管侵犯(HR 2.2,P<.001)、ER阳性(HR 0.64,P=.015)、接受辅助化疗(HR 0.52,P=.035)、黑人种族(HR 2.87,P<.001)。
  • ≤35岁患者局部失败风险高于36–50岁组(HR 2.2,95%CI 1.8–2.6,P<.001)和51–70岁组(HR 3.1,95%CI 2.45–3.9,P<.001)。
  • 第二恶性肿瘤5年和10年累积发生率分别为2.2%和4.4%。
  • 接受放疗与第二恶性肿瘤或对侧乳腺癌无显著关联。

关键数值与推荐

  • ≤35岁患者局部失败风险较36–50岁组高(HR 2.2,95%CI 1.8–2.6,P<.001),较51–70岁组高(HR 3.1,95%CI 2.45–3.9,P<.001)。
  • 总生存相关因素:肿瘤大小HR 1.14(P=.02)、脉管侵犯HR 2.2(P<.001)、ER阳性HR 0.64(P=.015)、辅助化疗HR 0.52(P=.035)、黑人种族HR 2.87(P<.001)。
  • 第二恶性肿瘤5年累积发生率2.2%,10年累积发生率4.4%。

临床怎么用

  • 对≤35岁乳腺癌患者应关注更高的局部失败风险,并考虑适当强化局部治疗。
  • 保乳治疗可作为≤35岁患者的合适选择。
  • 术后放疗的已知适应证不应因对第二恶性肿瘤的担忧而改变。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Breast cancer diagnosis at a very young age has been independently correlated with worse outcomes. Appropriately intensifying treatment in these patients is warranted, even as we acknowledge the risks of potentially mutagenic adjuvant therapies. We examined local control, distant control, overall survival, and secondary malignancy rates by age cohort and by initial surgical strategy. METHODS AND MATERIALS: Female patients less than or equal to 35 years of age diagnosed with invasive breast cancer from January 1, 1990, to December 31, 2010, were identified. Control groups of those aged 36 to 50 years (n = 6246) and 51 to 70 years (n = 7294) were delineated from an institutional registry. Clinicopathologic and follow-up information was collected. Chi-squared test was used to compare frequencies of categorical variables. Survival endpoints were evaluated using Kaplan-Meier methodology. RESULTS: A total of 529 patients ≤35 years of age met criteria for analysis. The median age of diagnosis was 32 years (range 20-35). Median follow-up was 10.3 years. On multivariable analysis, factors associated with overall survival (OS) were tumor size (hazard ratio [HR] 1.14, P = .02), presence of lymphovascular invasion (HR 2.2, P <.001), estrogen receptor positivity (HR 0.64, P = .015), receipt of adjuvant chemotherapy (HR 0.52, P = .035), and black race (HR 2.87, P <.001). The ultra-young were more likely to experience local failure compared with the aged 36 to 50 group (HR 2.2, 95% CI 1.8-2.6, P < .001) and aged 51 to 70 group (HR 3.1, 95% CI 2.45 - 3.9, P <.001). The cumulative incidence of secondary malignancies at 5 and 10 years was 2.2% and 4.4%, respectively. Receipt of radiation was not significantly associated with secondary malignancies or contralateral breast cancer. CONCLUSION: Survival and recurrence outcomes in breast cancer patients ≤35 years are worse compared with those aged 36 to 50 or 51 to 70 years. Based on our data, breast conservation therapy is appropriate for these patients, and the concern for second malignancies should not impinge on the known indications for postoperative radiation therapy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Billena C, Wilgucki M, Flynn J, et al. 10-Year Breast Cancer Outcomes in Women ≤35 Years of Age. Int J Radiat Oncol Biol Phys. 2020. PMID: 33371964. doi:10.1016/j.ijrobp.2020.10.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。